The stock of Alkermes Plc (NASDAQ:ALKS) is a huge mover today! About 294,236 shares traded hands. Alkermes Plc (NASDAQ:ALKS) has risen 39.56% since March 15, 2016 and is uptrending. It has outperformed by 34.07% the S&P500.
The move comes after 5 months positive chart setup for the $6.60B company. It was reported on Oct, 18 by Barchart.com. We have $59.12 PT which if reached, will make NASDAQ:ALKS worth $2.38B more.
Analysts await Alkermes Plc (NASDAQ:ALKS) to report earnings on November, 3. They expect $-0.20 EPS, up 52.38% or $0.22 from last year’s $-0.42 per share. After $-0.18 actual EPS reported by Alkermes Plc for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.
Alkermes Plc (NASDAQ:ALKS) Ratings Coverage
Out of 8 analysts covering Alkermes (NASDAQ:ALKS), 5 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 63% are positive. Alkermes has been the topic of 13 analyst reports since September 1, 2015 according to StockzIntelligence Inc. As per Friday, July 29, the company rating was maintained by Barclays Capital. Evercore initiated the shares of ALKS in a report on Thursday, May 26 with “Buy” rating. The firm has “Market Perform” rating given on Tuesday, July 26 by Cowen & Co. UBS maintained it with “Neutral” rating and $36 target price in Friday, January 22 report. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Buy” rating by Jefferies on Friday, July 29. The firm has “Overweight” rating by Morgan Stanley given on Tuesday, September 1. Leerink Swann maintained the stock with “Outperform” rating in Thursday, January 21 report. The stock has “Market Perform” rating given by Cowen & Co on Thursday, January 21. The stock has “Neutral” rating given by JP Morgan on Thursday, January 21. Barclays Capital maintained it with “Overweight” rating and $65 target price in Wednesday, July 13 report.
According to Zacks Investment Research, “Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes’ pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.”
Insitutional Activity: The institutional sentiment increased to 0.96 in 2016 Q2. Its up 0.25, from 0.71 in 2016Q1. The ratio is positive, as 31 funds sold all Alkermes Plc shares owned while 75 reduced positions. 34 funds bought stakes while 68 increased positions. They now own 135.77 million shares or 0.84% less from 136.92 million shares in 2016Q1.
Baker Bros Advsrs Lp accumulated 0.11% or 250,251 shares. State Street last reported 0.02% of its portfolio in the stock. Fiera Capital owns 6,400 shares or 0% of their US portfolio. Vanguard Grp has invested 0.03% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Mark Sheptoff Fin Planning Ltd Liability Corporation accumulated 0.01% or 300 shares. Atlantic Trust Ltd Company reported 160,898 shares or 0.05% of all its holdings. Bnp Paribas Arbitrage, a New York-based fund reported 61,444 shares. Polar Cap Llp reported 7,852 shares or 0.01% of all its holdings. Aqr Mngmt Limited Liability Co accumulated 185,338 shares or 0.01% of the stock. Kbc Gp Nv has invested 0.01% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Price T Rowe Associate Md holds 0.17% of its portfolio in Alkermes Plc (NASDAQ:ALKS) for 18.70 million shares. Solaris Asset Mgmt Lc holds 0% or 50 shares in its portfolio. Meditor Group Incorporated Limited owns 1.03M shares or 18.13% of their US portfolio. The Japan-based Blackrock Japan Company has invested 0.03% in Alkermes Plc (NASDAQ:ALKS). Barclays Plc, a United Kingdom-based fund reported 19,224 shares.
More news for Alkermes Plc (NASDAQ:ALKS) were recently published by: Businesswire.com, which released: “Alkermes Launches Competitive Grants Program to Support People Affected by …” on September 12, 2016. Seekingalpha.com‘s article titled: “Alkermes Plc (ALKS) Richard Pops on Q2 2016 Results – Earnings Call Transcript” and published on July 28, 2016 is yet another important article.
ALKS Company Profile
Alkermes Public Limited Company, incorporated on May 4, 2011, is a biopharmaceutical company. The Firm is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Firm has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. The Company’s products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. The Company’s product platforms include injectable extended release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.